Literature DB >> 28096938

Sunitinib toxicity management - a practical approach.

Sandeep Sehdev1.   

Abstract

This article summarizes the adverse events (AEs) of sunitinib that are commonly encountered in a community oncology practice, and provides practical recommendations for their management based on the available literature and on the author's own experience.

Entities:  

Year:  2016        PMID： 28096938      PMCID： PMC5215303          DOI： 10.5489/cuaj.4296

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


  14 in total

Review 1.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Authors:  Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Journal:  Oncologist       Date:  2011-04-13

2.  Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.

Authors:  Bruce A Feinberg; Pradeep Jolly; Si-Tien Wang; Barry Fortner; Jeffrey Scott; James Gilmore; Maureen P Neary; Mei Sheng Duh
Journal:  Med Oncol       Date:  2011-04-09       Impact factor: 3.064

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Authors:  Jayesh Desai; Leila Yassa; Ellen Marqusee; Suzanne George; Mary C Frates; Ming Hui Chen; Jeffrey A Morgan; Samuel S Dychter; P Reed Larsen; George D Demetri; Erik K Alexander
Journal:  Ann Intern Med       Date:  2006-11-07       Impact factor: 25.391

Review 5.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

6.  Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists.

Authors:  Janelle Nicole Ruiz; Viswanath Reddy Belum; Patricia Creel; Allen Cohn; Michael Ewer; Mario E Lacouture
Journal:  Clin Genitourin Cancer       Date:  2014-05-16       Impact factor: 2.872

7.  Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

Authors:  Toni K Choueiri; Mei Sheng Duh; Jessica Clement; Ashley J Brick; Miranda J Rogers; Christabel Kwabi; Karishma Shah; Andrew G Percy; Lucia Antràs; Sujata S Jayawant; Kristina Chen; Si-Tien Wang; Andi Luka; Maureen P Neary; David McDermott; William K Oh
Journal:  BJU Int       Date:  2009-10-26       Impact factor: 5.588

8.  Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.

Authors:  Elaine Wong; Lee S Rosen; Marilyn Mulay; Andy Vanvugt; Melissa Dinolfo; Chisato Tomoda; Masahiro Sugawara; Jerome M Hershman
Journal:  Thyroid       Date:  2007-04       Impact factor: 6.568

Review 9.  Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.

Authors:  Rudolph M Navari; Jim M Koeller
Journal:  Ann Pharmacother       Date:  2003-09       Impact factor: 3.154

10.  Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.

Authors:  William K Oh; David McDermott; Camillo Porta; Antonin Levy; Reza Elaidi; Florian Scotte; Robert Hawkins; Daniel Castellano; Joaquim Bellmunt; Sun Young Rha; Jong-Mu Sun; Paul Nathan; Bruce A Feinberg; Jeffrey Scott; Ray McDermott; Jin-Hee Ahn; John Wagstaff; Yen-Hwa Chang; Yen-Chuan Ou; Paul Donnellan; Chao-Yuan Huang; John McCaffrey; Po-Hui Chiang; Cheng-Keng Chuang; Caroline Korves; Maureen P Neary; Jose R Diaz; Faisal Mehmud; Mei Sheng Duh
Journal:  Int J Oncol       Date:  2013-11-15       Impact factor: 5.650
View more
  5 in total

Review 1.  Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients.

Authors:  Monika Dudzisz-Śledź; Anna Klimczak; Elżbieta Bylina; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

Review 2.  Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.

Authors:  Ahmed Badran; Mahmoud A Elshenawy; Amgad Shahin; Ali Aljubran; Ahmed Alzahrani; Abdelmoneim Eldali; Shouki Bazarbashi
Journal:  JCO Glob Oncol       Date:  2020-02

Review 3.  Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients.

Authors:  Monika Dudzisz-Śledź; Elżbieta Bylina; Paweł Teterycz; Piotr Rutkowski
Journal:  Drugs Aging       Date:  2021-03-02       Impact factor: 3.923

Review 4.  Molecular Delivery of Cytotoxic Agents via Integrin Activation.

Authors:  Martina Cirillo; Daria Giacomini
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

Review 5.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.